Literature DB >> 12216271

Mechanisms of antibiotic resistance in Pseudomonas aeruginosa.

P A Lambert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12216271      PMCID： PMC1308633     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  22 in total

Review 1.  Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms.

Authors:  K Poole
Journal:  J Mol Microbiol Biotechnol       Date:  2001-04

2.  Of Pseudomonas, porins, pumps and carbapenems.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

3.  The amino terminus of Pseudomonas aeruginosa outer membrane protein OprF forms channels in lipid bilayer membranes: correlation with a three-dimensional model.

Authors:  F S Brinkman; M Bains; R E Hancock
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

Review 4.  Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.

Authors:  E B Chaïbi; D Sirot; G Paul; R Labia
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

5.  Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains.

Authors:  Haluk Vahaboglu; Figen Coskunkan; Ozlem Tansel; Recep Ozturk; Nursu Sahin; Iftahar Koksal; Bekir Kocazeybek; Muserref Tatman-Otkun; Hakan Leblebicioglu; Mehmet Ali Ozinel; Halis Akalin; Sesin Kocagoz; Volkan Korten
Journal:  J Med Microbiol       Date:  2001-07       Impact factor: 2.472

Review 6.  Mechanisms of biofilm resistance to antimicrobial agents.

Authors:  T F Mah; G A O'Toole
Journal:  Trends Microbiol       Date:  2001-01       Impact factor: 17.079

Review 7.  Beta-lactamase inhibitors: agents to overcome bacterial resistance.

Authors:  S N Maiti; O A Phillips; R G Micetich; D M Livermore
Journal:  Curr Med Chem       Date:  1998-12       Impact factor: 4.530

8.  Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.

Authors:  T Akasaka; M Tanaka; A Yamaguchi; K Sato
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

9.  Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.

Authors:  D L MacLeod; L E Nelson; R M Shawar; B B Lin; L G Lockwood; J E Dirk; G H Miller; J L Burns; R L Garber
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

10.  Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.

Authors:  C J Henwood; D M Livermore; D James; M Warner
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790
View more
  109 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

2.  Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.

Authors:  H M H N Bandara; A Harb; D Kolacny; P Martins; H D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-08-26       Impact factor: 3.246

3.  Identification of Pseudomonas aeruginosa genes involved in virulence and anaerobic growth.

Authors:  Melanie J Filiatrault; Kristin F Picardo; Helen Ngai; Luciano Passador; Barbara H Iglewski
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa.

Authors:  Maytham Hussein; Mei-Ling Han; Yan Zhu; Qi Zhou; Yu-Wei Lin; Robert E W Hancock; Daniel Hoyer; Darren J Creek; Jian Li; Tony Velkov
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.

Authors:  Hajira Bilal; Phillip J Bergen; Tae Hwan Kim; Seung Eun Chung; Anton Y Peleg; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Activation of ExoU phospholipase activity requires specific C-terminal regions.

Authors:  Katherine M Schmalzer; Marc A Benson; Dara W Frank
Journal:  J Bacteriol       Date:  2010-01-22       Impact factor: 3.490

7.  The antimicrobial effect of blue light: What are behind?

Authors:  Tianhong Dai
Journal:  Virulence       Date:  2017-01-04       Impact factor: 5.882

8.  Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.

Authors:  Veronica B Hubble; Brittany A Hubbard; Bradley M Minrovic; Roberta J Melander; Christian Melander
Journal:  ACS Infect Dis       Date:  2018-11-29       Impact factor: 5.084

9.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

10.  Molecular basis for the recognition of structurally distinct autoinducer mimics by the Pseudomonas aeruginosa LasR quorum-sensing signaling receptor.

Authors:  Yaozhong Zou; Satish K Nair
Journal:  Chem Biol       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.